COMPANY PROFILE // THE 014 REPORT
Femasys Inc.
FEMY (Nasdaq)
Assembled from 3 government sources in 2.0 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-11-02: a pattern of leadership change.
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-01-15 and 3 more times (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
FEMASYS INC is an SEC-registered operating company in surgical & medical instruments & apparatus, incorporated in DE, based in Suwanee, GA; listed as FEMY (Nasdaq).[source] It reported revenue of $2.3 million for the fiscal year ended 2025-12-31.[source] It has filed 74 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are Dauntless Investment Group, LLC, VANGUARD CAPITAL MANAGEMENT LLC, JANE STREET GROUP, LLC (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; 3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-11-02.[source]
- red0
- amber2
- info0
- Dauntless Investment Group, LLC$7.8M
- VANGUARD CAPITAL MANAGEMENT LLC$260K
- JANE STREET GROUP, LLC$219K
- GEODE CAPITAL MANAGEMENT, LLC$129K
- UBS Group AG$78K
- CITADEL ADVISORS LLC$71K
- VANGUARD FIDUCIARY TRUST CO$52K
- OSAIC HOLDINGS, INC.$10K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Currie Daniel Scott · Chief Operating Officer (Officer) · latest Form 4 2025-06-04 · filing · LinkedIn search
- Elefant Dov · Chief Financial Officer (Officer) · latest Form 4 2026-03-27 · filing · LinkedIn search
- Lee-Sepsick Kathy · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-27 · filing · LinkedIn search
- Nicholas Kelley Stinson · Chief Commercial Officer (Officer) · latest Form 4 2025-07-01 · filing · LinkedIn search
- Sipos Jeremy Alexander · Chief Technology Officer (Officer) · latest Form 4 2026-02-17 · filing · LinkedIn search
- Eichenbaum Kenneth D. · Director · latest Form 4 2026-03-27 · filing · LinkedIn search
- Larsen Charles · Director · latest Form 4 2026-03-27 · filing · LinkedIn search
- Milnes Alistair · Director · latest Form 4 2025-06-27 · filing · LinkedIn search
- Silverman Joshua · Director · latest Form 4 2026-03-18 · filing · LinkedIn search
- Uzialko Edward R · Director · latest Form 4 2025-06-27 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Dechert LLP · Exhibit 5.1 legal opinion, S-3 filed 2026-09-03
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001339005 | source |
| EIN | 11-3713499 | source |
| Business address (SEC) | 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE, GA, 30024 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 3841 (surgical & medical instruments & apparatus): 149 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- STRYKER CORP · 101 SEC filings in 12 months · 1 flag · $502.2M federal (possible match)
- ORASURE TECHNOLOGIES INC · 69 SEC filings in 12 months · 2 flags · $480.7M federal (possible match)
- 3M CO · 124 SEC filings in 12 months · $465.5M federal (possible match)
- BOSTON SCIENTIFIC CORP · 110 SEC filings in 12 months · 1 flag · $140.1M federal (possible match)
- CERUS CORP · 71 SEC filings in 12 months · 2 flags · $126.6M federal (possible match)
- BAXTER INTERNATIONAL INC · 84 SEC filings in 12 months · 1 flag · $54.7M federal (possible match)
- Inspire Medical Systems, Inc. · 100 SEC filings in 12 months · 4 flags · $22.3M federal (possible match)
- ACCURAY INC · 103 SEC filings in 12 months · 4 flags · $13.9M federal (possible match)
- NeuroPace Inc · 61 SEC filings in 12 months · $10.3M federal (possible match)
- TELEFLEX INC · 64 SEC filings in 12 months · 1 flag · $9.4M federal (possible match)
- Cytosorbents Corp · 30 SEC filings in 12 months · 4 flags · $5.0M federal (possible match)
- IRADIMED CORP · 70 SEC filings in 12 months · 1 flag · $4.0M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- BICYCLE THERAPEUTICS plc · Alistair Milnes
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-13 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-02 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-09-29 filing 424B3 · SEC EDGAR
- 2026-09-28 filing EFFECT · SEC EDGAR
- 2026-09-03 filing S-3 · SEC EDGAR
- 2026-08-20 filing D · SEC EDGAR
- 2026-08-17 filing SCHEDULE 13D · SEC EDGAR
- 2026-08-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-14 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-11 filing 8-K items 1.01,3.02,9.01 · SEC EDGAR
- 2026-06-24 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-24 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-05 filing 8-K items 3.03,5.03,9.01 · SEC EDGAR
- 2026-06-04 filing 8-K items 7.01 · SEC EDGAR
- 2026-05-13 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-05-08 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-08 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-30 filing Proxy statement · SEC EDGAR
- 2026-04-30 filing ARS · SEC EDGAR
- 2026-04-30 filing DEFA14A · SEC EDGAR
- 2026-04-29 filing 8-K items 5.07 · SEC EDGAR
- 2026-04-06 filing Proxy statement · SEC EDGAR
- 2026-04-01 officer change 8-K items 5.02,8.01,9.01 · SEC EDGAR
- 2026-03-31 filing S-8 · SEC EDGAR
- 2026-03-31 filing Annual report (10-K) · SEC EDGAR
- 2026-03-31 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-27 filing PRE 14A · SEC EDGAR
- 2026-03-20 officer change 8-K items 1.01,3.02,5.02,9.01 · SEC EDGAR
- 2026-03-20 insider First Form 3/4/5 on record for Eichenbaum Kenneth D. (Director) · SEC Forms 3/4/5
170 earlier entries
- 2026-02-17 insider First Form 3/4/5 on record for Sipos Jeremy Alexander (Chief Technology Officer)
- 2026-01-15 filing 8-K items 3.01
- 2026-01-12 filing 424B3
- 2026-01-09 filing EFFECT
- 2026-01-07 filing CORRESP
- 2026-01-06 filing UPLOAD
- 2025-12-31 filing S-3
- 2025-12-23 filing 8-K items 8.01,9.01
- 2025-12-23 filing 424B3
- 2025-12-18 filing 8-K items 8.01,9.01
- 2025-12-09 filing EFFECT
- 2025-12-05 filing CORRESP
- 2025-12-04 filing S-3/A
- 2025-11-14 filing Quarterly report (10-Q)
- 2025-11-14 filing 8-K items 2.02,9.01
- 2025-11-14 filing D
- 2025-11-10 filing 8-K items 8.01,9.01
- 2025-11-07 filing 8-K items 1.01,3.02,9.01
- 2025-11-03 filing 8-K items 8.01,9.01
- 2025-10-21 filing 8-K items 3.01,9.01
- 2025-10-17 officer change 8-K items 5.02,9.01
- 2025-08-27 filing 8-K items 1.01,3.02,9.01
- 2025-08-27 filing 424B5
- 2025-08-25 filing EFFECT
- 2025-08-21 filing S-1/A
- 2025-08-20 filing CORRESP
- 2025-08-20 filing 8-K items 8.01,9.01
- 2025-08-20 filing Registration (S-1)
- 2025-08-19 filing CORRESP
- 2025-08-19 filing CORRESP
- 2025-08-12 filing UPLOAD
- 2025-08-08 filing DRSLTR
- 2025-08-08 filing DRS
- 2025-08-08 filing Quarterly report (10-Q)
- 2025-08-08 filing 8-K items 2.02,9.01
- 2025-08-06 filing 8-K items 8.01,9.01
- 2025-07-18 filing 8-K items 3.01
- 2025-07-09 filing UPLOAD
- 2025-07-03 filing 8-K items 1.01,3.02,9.01
- 2025-07-03 filing S-3
- 2025-07-01 filing 8-K items 8.01,9.01
- 2025-07-01 insider First Form 3/4/5 on record for Nicholas Kelley Stinson (Chief Commercial Officer)
- 2025-06-27 insider First Form 3/4/5 on record for Milnes Alistair (Director)
- 2025-06-27 insider First Form 3/4/5 on record for Silverman Joshua (Director)
- 2025-06-27 insider First Form 3/4/5 on record for Uzialko Edward R (Director)
- 2025-06-25 filing 8-K items 5.07
- 2025-06-25 filing 8-K items 8.01,9.01
- 2025-06-17 filing 8-K items 8.01,9.01
- 2025-06-10 filing D
- 2025-06-04 insider First Form 3/4/5 on record for Currie Daniel Scott (Chief Operating Officer)
- 2025-06-04 insider First Form 3/4/5 on record for Elefant Dov (Chief Financial Officer)
- 2025-06-04 insider First Form 3/4/5 on record for Lee-Sepsick Kathy (Chief Executive Officer)
- 2025-06-04 insider First Form 3/4/5 on record for Larsen Charles (Director)
- 2025-06-02 filing 8-K items 1.01,3.02,9.01
- 2025-06-02 filing 424B5
- 2025-05-29 filing 424B5
- 2025-05-23 filing 8-K items 3.01
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-04-28 filing ARS
- 2025-04-28 filing DEFA14A
- 2025-04-28 filing Proxy statement
- 2025-03-27 filing S-8
- 2025-03-27 filing Annual report (10-K)
- 2025-03-27 filing 8-K items 2.02,9.01
- 2025-03-18 filing 8-K items 8.01,9.01
- 2025-03-13 filing 8-K items 8.01,9.01
- 2024-11-12 filing 8-K/A items 2.02,9.01
- 2024-11-12 filing Quarterly report (10-Q)
- 2024-11-12 filing 8-K items 2.02,9.01
- 2024-10-29 filing 8-K items 7.01,9.01
- 2024-09-11 filing 8-K items 8.01,9.01
- 2024-09-09 filing 8-K items 8.01,9.01
- 2024-08-30 filing 8-K items 7.01,9.01
- 2024-08-29 filing 8-K items 8.01,9.01
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-07-12 filing 8-K items 5.07
- 2024-06-20 filing 8-K items 8.01,9.01
- 2024-06-07 filing Proxy statement
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-04-26 filing 10-K/A
- 2024-04-24 filing 8-K items 7.01,9.01
- 2024-04-05 filing S-8
- 2024-04-05 filing S-8
- 2024-03-28 filing Annual report (10-K)
- 2024-03-28 filing 8-K items 2.02,9.01
- 2024-03-20 filing 8-K items 8.01,9.01
- 2024-03-06 filing 8-K items 8.01,9.01
- 2024-02-28 filing 8-K items 7.01,8.01,9.01
- 2024-02-06 filing 8-K items 8.01,9.01
- 2023-12-08 filing EFFECT
- 2023-12-08 filing 424B3
- 2023-12-06 filing CORRESP
- 2023-12-05 filing UPLOAD
- 2023-11-30 filing S-3
- 2023-11-29 filing 8-K items 8.01,9.01
- 2023-11-22 filing D
- 2023-11-22 filing SC 13D
- 2023-11-21 officer change 8-K items 5.02
- 2023-11-15 officer change 8-K items 1.01,3.01,3.02,5.02,8.01,9.01
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-11-14 filing 8-K items 2.02,9.01
- 2023-10-11 filing 8-K items 8.01,9.01
- 2023-10-03 filing 8-K items 8.01,9.01
- 2023-10-03 filing 424B3
- 2023-09-27 filing 8-K items 7.01,8.01,9.01
- 2023-09-06 filing 8-K items 5.07
- 2023-08-10 filing Quarterly report (10-Q)
- 2023-08-10 officer change 8-K items 2.02,5.02,9.01
- 2023-08-07 filing Proxy statement
- 2023-08-03 filing 8-K items 8.01,9.01
- 2023-07-28 filing PRE 14A
- 2023-07-27 filing 8-K items 8.01,9.01
- 2023-07-24 filing 10-K/A
- 2023-07-14 filing EFFECT
- 2023-07-14 filing 424B3
- 2023-07-12 filing CORRESP
- 2023-07-07 filing CORRESP
- 2023-07-07 filing S-1/A
- 2023-07-05 filing UPLOAD
- 2023-06-26 filing 8-K items 7.01,8.01,9.01
- 2023-06-23 filing Registration (S-1)
- 2023-06-21 filing 8-K items 5.07
- 2023-06-15 officer change 8-K items 5.02,8.01,9.01
- 2023-06-08 filing 8-K items 8.01,9.01
- 2023-06-02 filing 8-K items 3.01
- 2023-05-16 filing DEFA14A
- 2023-05-15 filing ARS
- 2023-05-15 filing Proxy statement
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-05-11 filing 8-K items 2.02,7.01,9.01
- 2023-05-05 filing PRE 14A
- 2023-05-04 filing 8-K items 8.01,9.01
- 2023-04-28 filing 10-K/A
- 2023-04-20 filing 8-K items 1.01,3.02,8.01,9.01
- 2023-04-20 filing 424B3
- 2023-04-18 filing 8-K items 8.01,9.01
- 2023-04-05 filing S-8
- 2023-03-31 filing 8-K items 7.01,9.01
- 2023-03-30 filing Annual report (10-K)
- 2023-03-30 filing 8-K items 2.02,5.03,9.01
- 2023-03-13 filing 8-K items 8.01
- 2022-12-21 filing 8-K items 8.01,9.01
- 2022-11-10 filing Quarterly report (10-Q)
- 2022-11-10 filing 8-K items 2.02,9.01
- 2022-10-20 filing 8-K items 7.01,8.01,9.01
- 2022-10-12 filing 8-K items 8.01,9.01
- 2022-10-06 filing 8-K items 8.01,9.01
- 2022-09-29 filing 8-K items 8.01,9.01
- 2022-08-10 filing Quarterly report (10-Q)
- 2022-08-10 filing 8-K items 2.02,9.01
- 2022-08-02 filing 8-K items 7.01,9.01
- 2022-07-13 filing 424B3
- 2022-07-12 filing EFFECT
- 2022-07-12 filing 424B3
- 2022-07-07 filing CORRESP
- 2022-07-06 filing UPLOAD
- 2022-07-01 filing S-3
- 2022-06-09 filing 8-K items 5.07
- 2022-05-11 filing Quarterly report (10-Q)
- 2022-05-11 filing 8-K items 2.02,9.01
- 2022-04-26 filing DEFA14A
- 2022-04-26 filing Proxy statement
- 2022-03-24 filing S-8
- 2022-03-24 filing S-8
- 2022-03-24 filing Annual report (10-K)
- 2022-03-24 filing 8-K items 2.02,9.01
- 2022-02-28 filing 8-K items 7.01,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 30 days) 10-Q filed
- 2026-11-13 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-02 (within 30 days) 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-29 (older) 424B3 filed
- 2026-09-28 (older) EFFECT filed
- 2026-09-03 (older) S-3 filed
- 2026-08-20 (older) D filed
- 2026-08-14 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:FEMY The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
1 possible match held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1339005 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | FEMY / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 113713499 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001339005 | SEC EDGAR / IRS |
| CUSIP | 31447E204 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001339005 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $2,293,313 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-22 09:53 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$18,627,887 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 09:53 UTC | Report an error |
| Total assets (at 2025-12-31) | $20,724,177 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 09:53 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $5,869,302 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 09:53 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $9,266,353 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 09:53 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:53 UTC | Report an error |
| SIC industry | 3841 Surgical & Medical Instruments & Apparatus | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:53 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:53 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:53 UTC | Report an error |
| Business address | 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE, GA, 30024 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:53 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:53 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$18,690,565 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 09:53 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $525,007 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 09:53 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $1,518,100 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 09:53 UTC | Report an error |
| Form D total offering amount (D filed 2026-08-20) | $30,000,000 | 2026-08-20 | D | as filed | 2026-11-22 09:53 UTC | Report an error |
| Form D total amount sold (D filed 2026-08-20) | $30,000,000 | 2026-08-20 | D | as filed | 2026-11-22 09:53 UTC | Report an error |
| Form D industry group | Biotechnology | 2026-08-20 | D | as filed | 2026-11-22 09:53 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2026-08-20 | D | as filed | 2026-11-22 09:53 UTC | Report an error |
| Form D date of first sale | 2026-08-10 | 2026-08-20 | D | as filed | 2026-11-22 09:53 UTC | Report an error |
| Plan (pension, plan no. 001) | FEMASYS INC. 401(K) PLAN: 75 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-22 09:53 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001140361-26-043797
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $404,597 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001140361-26-043797 | 2026-11-22 09:53 UTC | Report an error |
| Net income (loss) | -$4,564,815 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001140361-26-043797 | 2026-11-22 09:53 UTC | Report an error |
| Interest expense | $200,415 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001140361-26-043797 | 2026-11-22 09:53 UTC | Report an error |
| Cash and cash equivalents | $23,913,946 | at 2026-09-30 | 10-Q | 2026-11-13 | 0001140361-26-043797 | 2026-11-22 09:53 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing 10-Q filed
- 2026-11-13 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-02 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-29 Filing 424B3 filed
- 2026-09-28 Filing EFFECT filed
- 2026-09-03 Filing S-3 filed
- 2026-08-20 Filing D filed
- 2026-08-14 Filing 10-Q filed
- 2026-08-14 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-11 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-07-07 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-06-24 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-06-24 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-05 Filing 8-K filed: Item 3.03 rights of holders modified; Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-06-04 Filing 8-K filed: Item 7.01 Regulation FD disclosure
- 2026-05-13 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-08 Filing 10-Q filed
- 2026-05-08 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-30 Filing DEF 14A filed
- 2026-04-30 Filing ARS filed
- 2026-04-30 Filing DEFA14A filed
- 2026-04-29 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-04-06 Filing DEF 14A filed
- 2026-04-01 Filing 8-K filed: Item 5.02 officer or director change; Item 8.01 other event; Item 9.01 exhibits
- 2026-03-31 Filing S-8 filed
2 earlier entries
- 2026-03-31 Filing 10-K filed
- 2006-01-01 Record plan effective date: FEMASYS INC. 401(K) PLAN
8-K item text, as filed (excerpts)
- 2026-11-13 8-K Item 2.02
Results of Operations and Financial Condition. Other Events On November 13, 2026 Femasys Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by… the 8-K · retrieved 2026-11-22 09:53 UTC - 2026-11-02 8-K Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 30, 2026, Kenneth D. Eichenbaum, M.D., M.S.E., informed the Board of Directors (the “Board”) of Femasys Inc. (the “Company”) of his resignation as a director of the Company, effective as of that date. Dr. Eichenbaum’s resignation was in connection with Pointillist Global Macro Series of Pointillist Partners LLC’s termination of its right to nominate an individual to serve on the Board pursuant to that certain Securities Purchase Agreement, dated November 3, 2025, by and among the Company and certain accredited investors. Dr.… the 8-K · retrieved 2026-11-22 09:53 UTC - 2026-11-02 8-K Item 7.01
Regulation FD Disclosure. On October 30, 2026, the Company issued a press release announcing Mr. Moorhead’s appointment as a director of the Company. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific… the 8-K · retrieved 2026-11-22 09:53 UTC - 2026-08-14 8-K Item 2.02
Results of Operations and Financial Condition. On August 14, 2026 Femasys Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing… the 8-K · retrieved 2026-11-22 09:53 UTC - 2026-08-11 8-K Item 1.01
Entry into a Material Definitive Agreement. Private Placement On August 7, 2026, Femasys Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of (i) 5,013,559 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to 4,361,440 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) accompanying warrants to purchase an aggregate of 18,749,998 shares of Common Stock. For each share of Common… the 8-K · retrieved 2026-11-22 09:53 UTC - 2026-08-11 8-K Item 3.02
Unregistered Sales of Equity Securities The matters described in Item 1.01 of this Current Report on Form 8-K related to the Private Placement are incorporated herein by reference. The Private Placement is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. Each of the Purchasers has represented to the Company that it is an accredited investor within the meaning of Rule 501(a) of Regulation D and that it is acquiring the Securities… the 8-K · retrieved 2026-11-22 09:53 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | Dauntless Investment Group, LLC | $7,808,186 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $260,130 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 3 | JANE STREET GROUP, LLC | $219,495 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | $129,253 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 5 | UBS Group AG | $78,488 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 6 | CITADEL ADVISORS LLC | $70,730 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 7 | VANGUARD FIDUCIARY TRUST CO | $52,217 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 8 | OSAIC HOLDINGS, INC. | $10,019 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 9 | BlackRock, Inc. | $7,457 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
| 10 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $4,180 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:53 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchFemasys Inc. · exact legal name · sx:ctgov:hd935846fe0560526 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1339005.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001339005. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.